ISRCTN24909354进行中（未招募）1 期
Phase I trial: Parexel Code: PXL277433 [The full scientific title will be published within 30 months after the end of the trial]
适应症
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 88
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •Healthy human volunteers
排除标准
- •The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has ended.
研究者
相似试验
进行中（未招募）
1 期
Phase I trial: Parexel code: PXL 269850ISRCTN12117857MD Pharma88
进行中（未招募）
1 期
Phase I trial: PXL 272092ISRCTN45338135Hansa Biopharma (Sweden)8
已完成
不适用
Phase II trial, multicenter, first line Paclitaxel-Avelumab Treatment for inoperable AngiosarcomaKCT0003334Dong-A University Hospital33
进行中（未招募）
1 期
Phase I trial - 2021-006930-37The Health Research Authority (HRA) has approved deferral of publication of the full details of the trial. The full details will be added to the study record within 30 months after the trial has endedISRCTN15751828Omeros Corporation (United States)12
已完成
1 期
PD0332991/Paclitaxel in Advanced Breast CancerBreast CancerNCT01320592Abramson Cancer Center at Penn Medicine28